IPSEN IN BRIEF
Our vision is to be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.
Discover Ipsen in two pages; our products and key figures, our objectives and our strategy.
27 July 2023 – 1 mins read
Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
The performance in the first half of the year is reflected in today’s upgrade to our full-year guidance. We look forward to more milestones and further expansion of the pipeline over time through additional external-innovation transactions. I am confident, as…
Ipsen H1 2023 results
Watch the webcast held on 27 July following the H1 2023 results announcement
INVESTING FOR GROWTH
We see everyone within the Ipsen investor community as a valued stakeholder who helps drive our overall success. Dedicated to transparency and ethical decision-making, we aim to provide investors with the resources they need to understand our company and how we plan to reach our ambitious targets.
Underpinned by a robust balance sheet and strong cash generation, we have the ambition to replenish our pipeline. With a successful strategy, we’re proud to be backed by an investor community that recognizes our positive progress.
The Ipsen investment case
Entire focus on Specialty Care
Opportunities for further growth across the three therapy areas
A well-balanced & expanded presence around the world
A good mix of new molecules and lifecycle management
Fueling the expansion of the pipeline across the therapy areas
Strong balance sheet & cash generation
Free cash flow >€800m in 2022
Strong results backed by innovation
Our vision is to be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience. We delivered strong results in 2022. With a geographically balanced model, we delivered growth across total sales and core operating income.
We are dedicated to providing investors with the tools they need to understand our company and goals. Our events offer investors the opportunity to meet our management and investor-relations team and learn more about our strategy.
Innovating for a healthy tomorrow
Our robust development pipeline, backed by our expertise and external-innovation strategy, supports patients’ health outcomes across Oncology, Rare Disease and Neuroscience.
We aim to transparently communicate to our investor community our analyst coverage, ADR program and shareholding structure.
Information on voting rights updates, combined shareholders’ meeting and our share buyback program. View the publications and press releases related to regulated information.
FIVE-YEAR STOCK INFORMATION
Share price and stock information, benchmark, orders, transactions: discover the data related to Ipsen’s shares.